1-17 of 17
Gareth P Gregory
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tzoran, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Alex F. Herrera
Journal: Blood
Blood (2023) 142 (Supplement 1): 4440.
https://doi.org/10.1182/blood-2023-182019
Published: 2023
Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, John Timmerman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1693.
https://doi.org/10.1182/blood-2023-182128
Published: 2023
Journal Articles

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Armando Santoro, Nathalie A. Johnson, Kerry J. Savage, Abraham Avigdor, Ali Bazargan, Peter Borchmann, Robin Gasiorowski, Gareth P. Gregory, Yair Herishanu, Sumit Madan, Leonard Minuk, Gerardo Musuraca, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Pier Luigi Zinzani
Journal: Blood
Blood (2023) 142 (Supplement 1): 1725.
https://doi.org/10.1182/blood-2023-182536
Published: 2023
Journal Articles

A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-Cell Malignancies

Bruce D. Cheson, Geoffrey P. Shouse, Sarit Assouline, Katharine L. Lewis, Eliza A Hawkes, Talha Munir, Andrew S. Davies, Petra Langerbeins, Constantine S. Tam, Gareth P. Gregory, Michael Y. Choi, William Sun, Siminder K. Atwal, Wan-Jen Hong, Clémentine Sarkozy
Journal: Blood
Blood (2023) 142 (Supplement 1): 6324.
https://doi.org/10.1182/blood-2023-182434
Published: 2023
Journal Articles

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Genevive H. Hernandez, John So, Kathryn A. Logronio, Maya F. Kotturi, Won Seog Kim, Philippe Armand, Chan Y. Cheah, Ajay K. Gopal, Ian W. Flinn, Gareth P. Gregory, Matthew J. Matasar, Loretta J. Nastoupil, Catherine S. Diefenbach, Sung-Soo Yoon, Matthew Ku, Ibrahim Qazi, Maya K. Leabman, Iris Sison, Bruce A. Keyt, Chris H. Takimoto, Thomas J. Manley, Elizabeth L. Budde
Journal: Blood
Blood (2022) 140 (Supplement 1): 6436–6438.
https://doi.org/10.1182/blood-2022-163235
Published: 2022
Journal Articles

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment

John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tsoran-Rosenthal, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Akash Nahar, Alex F. Herrera
Journal: Blood
Blood (2022) 140 (Supplement 1): 768–770.
https://doi.org/10.1182/blood-2022-166670
Published: 2022
Journal Articles

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, John Palcza, Pallavi Pillai, Akash Nahar, John Timmerman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6540–6542.
https://doi.org/10.1182/blood-2022-166846
Published: 2022
Journal Articles

Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance

Pietro R Di Ciaccio, Belinda Campbell, Kylie D Mason, Mohamed Shanavas, Matthew Greenwood, Gareth P Gregory, Renee Eslick, Giselle Kidson-Gerber, Catherine Tang, Kirk L Morris, Portia Smallbone, Xavier Badoux, Michael J Shipton, Sean J McKeague, Jenna Langfield, Kathryn Goss, Nada Hamad
Journal: Blood
Blood (2021) 138 (Supplement 1): 882.
https://doi.org/10.1182/blood-2021-150538
Published: 2021
Journal Articles

High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients

Katharine Louise Lewis, Lasse H. Jakobsen, Diego Villa, Sabela Bobillo, Karin Ekstroem Smedby, Kerry J. Savage, Toby A. Eyre, Kate Cwynarski, Paris L Caporn, Joan Van Zyl, Magdalena Klanova, Marek Trněný, Robert Puckrin, Douglas A. Stewart, Mark J Bishton, Christopher P. Fox, Aung M Tun, Gita Thanarajasingam, Faouzi Djebbari, Erel Joffe, Sandra Eloranta, Sara Harrysson, Laurie H. Sehn, Seth M Maliske, Kittika Poonsombudlert, Xiao Guo, Greg Hapgood, Kate Manos, Eliza Hawkes, Jahanzaib Khwaja, Adrian Minson, Michael Dickinson, Andreas Kiesbye Øvlisen, Gareth P Gregory, Michael Gilbertson, Isaac T Streit, Hamish W Scott, Matthew Ku, Sanjay de Mel, Kar Ying Yong, Liu Xin, Mridula Mokoonlall, Dipti Talaulikar, Nicholas L McVilly, Anna Johnston, Matthew J Brunner, Priyanka A Pophali, Matthew J. Maurer, Tarec Christoffer El-Galaly, Chan Yoon Cheah
Journal: Blood
Blood (2021) 138 (Supplement 1): 181.
https://doi.org/10.1182/blood-2021-146737
Published: 2021
Journal Articles

Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA)

Maciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, Briony Shaw, Michelle Poon, Erin Paul, Matthew Ku, Mark Wong, Ashley Beekman, Michael Krigstein, Pietro R Di Ciaccio, Joel Wight, Caitlin Coombes, Michael Gilbertson, Amanda Tey, Jake Shortt, Chandramouli Nagarajan, Maya Latimer, Dipti Talaulikar, Nada Hamad, Sumita Ratnasingam, Tara Cochrane, Eliza Hawkes, Chan Yoon Cheah, Stephen Opat, Gareth P Gregory
Journal: Blood
Blood (2021) 138 (Supplement 1): 2532.
https://doi.org/10.1182/blood-2021-145959
Published: 2021
Journal Articles

A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies

Elizabeth Budde, Ajay K Gopal, Won Seog Kim, Ian W. Flinn, Chan Yoon Y. Cheah, Loretta Nastoupil, Matthew J. Matasar, Catherine S. Diefenbach, Gareth P Gregory, Ibrahim Qazi, Ching-Fai Pang, Maya Leabman, Genevive Hernandez, Iris Sison, Bruce A. Keyt, Daniel Chen, Philippe Armand
Journal: Blood
Blood (2021) 138 (Supplement 1): 132.
https://doi.org/10.1182/blood-2021-153355
Published: 2021
Journal Articles

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

Scott Boiko, Theresa Proia, Maryann San Martin, Gareth P. Gregory, Michelle Min Wu, Neeraj Aryal, Maureen Hattersley, Wenlin Shao, Jamal C. Saeh, Stephen E. Fawell, Ricky W. Johnstone, Lisa Drew, Justin Cidado
Journal: Blood
Blood (2021) 137 (21): 2947–2957.
https://doi.org/10.1182/blood.2020008528
Published: 2021
Includes: Supplemental data
Journal Articles

Prolonged Lymphopenia and Infection Risk Is Mitigated By Antimicrobial Prophylaxis in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Treated with Bendamustine +/- Anti-CD20 Antibody: The Australasian Lymphoma Alliance Experience

Kate Manos, MBBS, Masa Lasica, MD, Andrew Grigg, MBBS, MD FRACP, FRCPA, Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Jonathan Wong, MBBS, Usha Chandra Sekaran, Joel Wight, Zhong Goh, Hayden Jina, Llewyn Butler, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA, Gareth P. Gregory, Shane A Gangatharan, MBBS, FRACP, FRCPA, Tara Cochrane, MBBS,FRCPA,FRACP, Kristen Piper, Leonid Churilov, Eliza A Hawkes, FRACP,MDMBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–49.
https://doi.org/10.1182/blood-2020-138642
Published: 2020
Journal Articles

Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial

Sarit E Assouline, MD MSc, Won Seog Kim, MD PhD, Laurie H. Sehn, MDMPH, Stephen J. Schuster, MD, Chan Yoon Cheah, MBBS, Loretta J. Nastoupil, MD, Mazyar Shadman, Sung-Soo Yoon, MD PhD, Matthew J Matasar, MD, Catherine Diefenbach, MD, Gareth P. Gregory, Nancy L. Bartlett, MD, Michael C. Wei, Michelle Y. Doral, Shen Yin, Raluca Negricea, Chi-Chung Li, Elicia M. Penuel, Huang Huang, L. Elizabeth Budde
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–44.
https://doi.org/10.1182/blood-2020-135839
Published: 2020
Journal Articles

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Stephen J Schuster, MD, Nancy L Bartlett, MD, Sarit Assouline, MD, Sung-Soo Yoon, MD PhD, Francesc Bosch, MD PhD, Laurie H Sehn, MD, Chan Y. Cheah, Mazyar Shadman, MD MPH, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Matthew Ku, MBBS, FRACP, FRCPA, PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Antonia Kwan, MD PhD MRCPCH, Kasra Yousefi, MSc, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Lihua E Budde, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 6.
https://doi.org/10.1182/blood-2019-123742
Published: 2019
Journal Articles

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Constantine S. Tam, MBBS, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Aichun Liu, MD, Anna M. Johnston, Weili Zhao, MD PhD, Fernando Roncolato, BMed, FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Wenyu Li, MD PhD, Ted Shih, PharmD, Xiaoping Zhang, MD MS, Ken Wu, PhD, Yuan Liu, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 1594.
https://doi.org/10.1182/blood-2019-125485
Published: 2019
Journal Articles

Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies

Philippe Armand, Pier Luigi Luigi Zinzani, MD, John Palcza, Jane Anne Healy, Akash Nahar, Patricia Marinello, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 1548.
https://doi.org/10.1182/blood-2019-127474
Published: 2019